摘要
目的研究多沙唑嗪联合帕罗西汀治疗非细菌性慢性前列腺炎的效果。方法随机选取2019年1—12月福建省龙岩市第二医院收治的50例非细菌性慢性前列腺炎患者为研究对象,根据数字随机法分为对照组、研究组,各25例。研究组采取多沙唑嗪联合帕罗西汀治疗,对照组采取多沙唑嗪治疗,观察并比较两组患者在治疗前、后的慢性前列腺炎症状评分(NIH-CPSI)、不良情绪、治疗效果及并发症发生情况。结果治疗后,两组不良情绪、NIH-CPSI评分均较治疗前降低,且研究组低于对照组,差异有统计学意义(P<0.05)。研究组的总有效率96.00%高于对照组的68.00%,差异有统计学意义(χ^(2)=4.878,P<0.05)。研究组的并发症发生率为8.00%显著低于对照组的36.00%,差异有统计学意义(χ^(2)=5.711,P<0.05)。结论对非细菌性慢性前列腺炎采取多沙唑嗪联合帕罗西汀治疗,能够降低NIH-CPSI评分,改善患者的不良情绪,治疗的效果较好,安全性较高。.
Objective To study the effect of doxazosin combined with paroxetine on non-bacterial chronic prostatitis.Methods Fifty patients with non bacterial chronic prostatitis admitted to the Second Hospital of Longyan City,Fujian Province from January to December 2019 were randomly selected as the research subjects.They were randomly divided into a control group and a study group based on numerical randomization,with 25 patients in each group.The study group was treated with doxazosin combined with paroxetine,and the control group was treated with doxazosin.The chronic prostatitis symptom score(NIH-CPSI),bad mood before and after treatment,treatment effect and complications of the two groups were observed and compared.Results After treatment,the negative emotions and NIH-CPSI scores of both groups decreased compared to before treatment,and the study group was lower than the control group,and the difference was statistically significant(P<0.05).The total effective rate of 96.00%in the study group was higher than 68.00%in the control group,the difference was statistically significant(χ^(2)=4.878,P<0.05).The incidence of complications in the study group was 8.00%,significantly lower than 36.00%in the control group,the difference was statistically significant(χ^(2)=5.711,P<0.05),Conclusion Doxazosin combined with paroxetine in the treatment of non-bacterial chronic prostatitis can reduce the NIH-CPSI score and improve the adverse mood of patients.The therapeutic effect is good.
作者
刘春生
罗建斌
卢华荣
LIU Chunsheng;LUO Jianbin;LU Huarong(Department of Urology,Longyan Second Hospital,Longyan,Fujian Province,364000 China)
出处
《中外医疗》
2023年第14期98-101,106,共5页
China & Foreign Medical Treatment
